Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100540833> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2100540833 abstract "textabstractThe prodrug mycophenolate mofetil contains the active compound mycophenolic acid (MPA), which has immunosuppressive properties. It is used to prevent acute rejection after solid organ transplantation. In renal transplantation, the dose recommendation for mycophenolate mofetil is 1000 mg twice daily for adult patients. This fixed dose strategy for mycophenolate mofetil is remarkable in the field of transplantation as most other immunosuppressive drugs are used in an individualised dose, often based on drug concentration measurements. During the use of mycophenolate mofetil in the past ten years, data have become available which provide four reasons to question the justification of a fixed mycophenolate mofetil dose. The first reason is the existence of a concentration-effect relationship: the risk for acute rejection is lower when exposure to MPA is higher. This has led to the adoption of a target exposure range for MPA area-under-the-curve (AUC0-12) values of 30 to 60 mg*h/L. The second reason is the large between-patient variability in MPA pharmacokinetics, reported to be more than 10-fold for MPA AUC0-12. The third reason is that MPA exposure increases over time after transplantation despite a fixed dose. Finally, exposure to MPA is significantly influenced by the use of several other drugs. The result of these four factors is that with the use of a standard dose of mycophenolate mofetil, an important subset of renal transplant recipients will have MPA exposure outside the target range, and may therefore be at risk for acute rejection or toxicity. Individualisation of the mycophenolate mofetil dose is likely to improve exposure to MPA and may optimise clinical outcome. The aim of this thesis was to develop recommendations about when and how to individualise the mycophenolate mofetil dose. Two hypotheses in this regard were addressed, formulated in chapter 1.2. The first was that demographic factors that contribute to the variability in the pharmacokinetics of MPA may serve as a rationale for mycophenolate mofetil dose individualisation (chapters 2.1 to 2.6, and 4.1). The second was that therapeutic drug monitoring of MPA provides a suitable tool for mycophenolate mofetil dose individualisation (chapters 3.1 and 3.2)." @default.
- W2100540833 created "2016-06-24" @default.
- W2100540833 creator A5019108128 @default.
- W2100540833 date "2007-01-24" @default.
- W2100540833 modified "2023-09-27" @default.
- W2100540833 title "Individualisation of Mycophenolate Mofetil Therapy: Explaining variability in mycophenolic acid pharmacokinetics and introducing therapeutic" @default.
- W2100540833 hasPublicationYear "2007" @default.
- W2100540833 type Work @default.
- W2100540833 sameAs 2100540833 @default.
- W2100540833 citedByCount "0" @default.
- W2100540833 crossrefType "journal-article" @default.
- W2100540833 hasAuthorship W2100540833A5019108128 @default.
- W2100540833 hasConcept C108215921 @default.
- W2100540833 hasConcept C112705442 @default.
- W2100540833 hasConcept C126322002 @default.
- W2100540833 hasConcept C126894567 @default.
- W2100540833 hasConcept C2778033501 @default.
- W2100540833 hasConcept C2780272996 @default.
- W2100540833 hasConcept C2909935303 @default.
- W2100540833 hasConcept C2911091166 @default.
- W2100540833 hasConcept C71924100 @default.
- W2100540833 hasConcept C76318530 @default.
- W2100540833 hasConcept C98274493 @default.
- W2100540833 hasConceptScore W2100540833C108215921 @default.
- W2100540833 hasConceptScore W2100540833C112705442 @default.
- W2100540833 hasConceptScore W2100540833C126322002 @default.
- W2100540833 hasConceptScore W2100540833C126894567 @default.
- W2100540833 hasConceptScore W2100540833C2778033501 @default.
- W2100540833 hasConceptScore W2100540833C2780272996 @default.
- W2100540833 hasConceptScore W2100540833C2909935303 @default.
- W2100540833 hasConceptScore W2100540833C2911091166 @default.
- W2100540833 hasConceptScore W2100540833C71924100 @default.
- W2100540833 hasConceptScore W2100540833C76318530 @default.
- W2100540833 hasConceptScore W2100540833C98274493 @default.
- W2100540833 hasLocation W21005408331 @default.
- W2100540833 hasOpenAccess W2100540833 @default.
- W2100540833 hasPrimaryLocation W21005408331 @default.
- W2100540833 hasRelatedWork W1544963560 @default.
- W2100540833 hasRelatedWork W1965775788 @default.
- W2100540833 hasRelatedWork W1971018450 @default.
- W2100540833 hasRelatedWork W1996063068 @default.
- W2100540833 hasRelatedWork W2024252223 @default.
- W2100540833 hasRelatedWork W2024619081 @default.
- W2100540833 hasRelatedWork W2072486418 @default.
- W2100540833 hasRelatedWork W2077087098 @default.
- W2100540833 hasRelatedWork W2078468538 @default.
- W2100540833 hasRelatedWork W2100133439 @default.
- W2100540833 hasRelatedWork W2102476485 @default.
- W2100540833 hasRelatedWork W2119693171 @default.
- W2100540833 hasRelatedWork W2286587306 @default.
- W2100540833 hasRelatedWork W2324741055 @default.
- W2100540833 hasRelatedWork W2351167015 @default.
- W2100540833 hasRelatedWork W2413772116 @default.
- W2100540833 hasRelatedWork W2416318875 @default.
- W2100540833 hasRelatedWork W2770407301 @default.
- W2100540833 hasRelatedWork W3141984122 @default.
- W2100540833 hasRelatedWork W2590989309 @default.
- W2100540833 isParatext "false" @default.
- W2100540833 isRetracted "false" @default.
- W2100540833 magId "2100540833" @default.
- W2100540833 workType "article" @default.